Abbott/TheraSense FDA panel rescheduled
This article was originally published in The Gray Sheet
Executive Summary
Diabetes test manufacturer is working with FDA to establish a panel date for the FreeStyle Navigator continuous glucose monitor system, which uses interstitial fluid, after the agency mistakenly issued and then retracted a notice that its Clinical Chemistry & Clinical Toxicology Devices Panel would review the device on Oct. 13. TheraSense submitted a PMA last November. Upon approval, FreeStyle will compete with Medtronic's Guardian CGMS. Roche/Disetronic is developing similar technology...
You may also be interested in...
Glucon Preps For 2005 Clinical Trial Of Continuous Blood Sugar Monitor
Clinical trials on the sensitivity and specificity of Glucon's continuous glucose monitor will begin in Q3 2005, according to Benny Pesach, PhD, founder and VP-research & development
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.